<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051311</url>
  </required_header>
  <id_info>
    <org_study_id>030077</org_study_id>
    <secondary_id>03-C-0077</secondary_id>
    <nct_id>NCT00051311</nct_id>
    <nct_alias>NCT00055744</nct_alias>
  </id_info>
  <brief_title>Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers</brief_title>
  <official_title>A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine &amp; Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and effectiveness of a modified stem cell transplant&#xD;
      procedure for treating cancers of the blood and immune system. Patients with cancers and&#xD;
      pre-cancerous conditions originating in blood or immune system cells can sometimes benefit&#xD;
      greatly from, and even be cured by, transplants of stem cells (cells produced by the bone&#xD;
      marrow that mature into blood cells). In addition to producing new bone marrow and restoring&#xD;
      normal blood production and immunity, the donated cells fight any residual tumor cells that&#xD;
      might have remained in the body, in what is called a graft-versus-tumor effect.&#xD;
&#xD;
      However, severe problems, and sometimes death, may follow these transplants as a result of&#xD;
      the high-dose chemotherapy and radiation that accompany the procedure. Also, donated immune&#xD;
      system cells called T cells sometimes attack healthy tissues in a reaction called&#xD;
      graft-versus-host-disease (GVHD), damaging organs such as the liver, intestines and skin.&#xD;
      This study will use the following strategies to try to reduce these risks:&#xD;
&#xD;
        -  induction chemotherapy to reduce patient's immunity in an attempt to prevent rejection&#xD;
           of the donated stem cells;&#xD;
&#xD;
        -  reduced-intensity conditioning chemotherapy that is easier for the body to tolerate and&#xD;
           involves a shorter period of complete immune suppression;&#xD;
&#xD;
        -  donation of immune cells called T helper type 2 (Th2) cells instead of T cells to try to&#xD;
           reduce the risk of serious GVHD;&#xD;
&#xD;
        -  treatment with methotrexate and cyclosporine to try to reduce the risk of serious GVHD.&#xD;
&#xD;
      Patients between 12 and 75 years of age with non-Hodgkin's lymphoma, Hodgkin's lymphoma,&#xD;
      multiple myeloma, chronic lymphocytic leukemia, chronic myelogenous leukemia, acute&#xD;
      myelogenous leukemia, acute lymphocytic leukemia, myelodysplasia, idiopathic myelofibrosis,&#xD;
      polycythemia vera, or chronic myelomonocytic leukemia may be eligible for this study.&#xD;
      Candidates will have a medical history, physical and dental examinations, blood and urine&#xD;
      tests (including a blood test for genetic match with the donor), lung and heart function&#xD;
      tests, and X-ray studies. A bone marrow biopsy may be done to evaluate disease status.&#xD;
      Patients with lymphoma may have a nuclear medicine test called a positron emission tomography&#xD;
      (PET) scan.&#xD;
&#xD;
      Participants will have a central venous line (large plastic tube) placed into a major vein.&#xD;
      This tube can stay in the body and be used during the entire treatment period to deliver the&#xD;
      donated stem cells and give medications, including chemotherapy and other drugs, antibiotics&#xD;
      and blood transfusions, and to withdraw blood samples. Treatment will start with induction&#xD;
      chemotherapy, which will include the drugs fludarabine, cyclophosphamide, etoposide,&#xD;
      doxorubicin, vincristine, and prednisone. Some patients may also receive an antibody called&#xD;
      rituximab. Patients will receive one to three cycles of this treatment, depending on their&#xD;
      response to the drugs. (One cycle consists of 5 days on drug therapy followed by a 16-day&#xD;
      rest period.) Several days before the transplant procedure, patients will start conditioning&#xD;
      chemotherapy with cyclophosphamide and fludarabine. Three days after the conditioning therapy&#xD;
      is completed, the stem cells will be infused. To help prevent GVHD, patients will take four&#xD;
      doses of methotrexate (by vein) shortly after the transplant, and cyclosporine (by mouth or&#xD;
      by vein) for about 6 months after the transplant.&#xD;
&#xD;
      The average hospital stay for stem cell transplantation is 3 to 4 weeks. After discharge,&#xD;
      patients will return for frequent follow-up visits for 3 months. Monthly visits will be&#xD;
      scheduled for the next 3 months, then every 3 months for the next 18 months, and less&#xD;
      frequently for a total of at least 5 years post-transplant. These visits will include bone&#xD;
      marrow aspirates and biopsies, blood draws, and other tests to monitor disease status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative for&#xD;
      refractory hematologic malignancies, but its application has been limited historically by&#xD;
      morbidity and mortality from conventional transplant preparative regimens and&#xD;
      graft-versus-host disease (GVHD). Donor T cells mediate GVHD and also help to eradicate&#xD;
      malignancies through an immune-dependent graft-versus-tumor effect. Efforts to decrease&#xD;
      preparative regimen toxicity have led to reduced-intensity or 'nonmyeloablative' regimens,&#xD;
      facilitating the study of allogeneic HSCT in a broader population. As a promising strategy&#xD;
      for reducing GVHD, donor T helper type 2 (Th2) cells were shown to abrogate T helper type 1&#xD;
      (Th1)-mediated GVHD without impairing engraftment in murine models of allogeneic HSCT. These&#xD;
      findings led to a phase I/II clinical study of donor Th2 cells for the prevention of GVHD&#xD;
      during reduced-intensity allogeneic HSCT (CC 99-C-0143); preliminary results suggest that a&#xD;
      randomized trial will be necessary to evaluate donor Th2 cells further.&#xD;
&#xD;
      In CC 99-C-0143, a novel induction chemotherapy regimen, etoposide phosphate, prednisone,&#xD;
      vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (EPOCH)-Fludarabine&#xD;
      (EPOCH-F), was well tolerated and effective for sequential host immune depletion. However, a&#xD;
      significant proportion of patients failed to achieve satisfactory disease control before&#xD;
      transplant, providing a basis for intensifying this induction regimen. Furthermore, the&#xD;
      initial 20 patients treated on this study experienced relatively high rates of acute GVHD and&#xD;
      considerable morbidity associated with cyclosporine monotherapy for GVHD prevention,&#xD;
      indicating that future studies should use more aggressive prophylaxis. These observations&#xD;
      warrant modifying our approach to allogeneic HSCT before undertaking a randomized study of&#xD;
      donor Th2 cells.&#xD;
&#xD;
      We now propose a pilot study of human leukocyte antigens (HLA)-matched, related,&#xD;
      reduced-intensity allogeneic HSCT in refractory hematologic malignancies, using an&#xD;
      intensified etoposide, vincristine, doxorubicin, prednisone, cyclophosphamide and fludarabine&#xD;
      (EPOCH-F) induction chemotherapy regimen with rituximab added for patients with cluster of&#xD;
      differentiation 20 (CD20)+ malignancies fludarabine, etoposide, prednisone, vincristine,&#xD;
      cyclophosphamide, and doxorubicin plus with or without rituximab (DA-EPOCH-F/R). This regimen&#xD;
      will be evaluated for toxicity and disease control before transplantation. GVHD prophylaxis&#xD;
      will consist of a standard dual-agent regimen, cyclosporine/methotrexate; the impact of this&#xD;
      change on hematopoietic recovery, donor/recipient chimerism, and the incidence of acute GVHD&#xD;
      will be assessed.&#xD;
&#xD;
      Immune reconstitution following allogeneic HSCT is an important research interest among&#xD;
      Experimental Transplantation and Immunology Branch Investigators. Current evidence suggests a&#xD;
      critical role for interleukin-7 (IL-7) in cluster of differentiation 4 (CD4)+ T cell&#xD;
      homeostasis, and interleukin-15 (IL-15) appears crucial to cluster of differentiation 8&#xD;
      (CD8)+ T cell and NK cell homeostasis. The relationships between these cytokines and&#xD;
      lymphocyte subpopulations have not been studied in the setting of allogeneic HSCT; such&#xD;
      analysis may enhance our understanding of engraftment kinetics, graft-versus-host disease,&#xD;
      and immune reconstitution. We will correlate serum IL-7 and IL-15 levels with changes in&#xD;
      circulating T-cell and natural killer (NK)-cell subpopulations during EPOCH-F/R induction&#xD;
      chemotherapy, after transplantation, and with the development of GVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2003</start_date>
  <completion_date type="Actual">September 25, 2014</completion_date>
  <primary_completion_date type="Actual">September 25, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</measure>
    <time_frame>At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)</time_frame>
    <description>Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</measure>
    <time_frame>At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)</time_frame>
    <description>Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Recipients Who Achieved Donor Chimerism at Day +14</measure>
    <time_frame>Day+14</time_frame>
    <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100</measure>
    <time_frame>Day+100</time_frame>
    <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients</measure>
    <time_frame>Up to cycle 3</time_frame>
    <description>Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Neutrophil Recovery</measure>
    <time_frame>Up to 2 months after stem cell transplant</time_frame>
    <description>Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Platelet Recovery</measure>
    <time_frame>Up to 2 months after stem cell transplant</time_frame>
    <description>Platelet recovery is defined as &gt;50,000 mm3 platelet cell count after transfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)</measure>
    <time_frame>At least 100 days after post reduced-intensity stem cell transplantation (RIST).</time_frame>
    <description>Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass &gt; 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Recipients With Non-serious Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 58 months and 13 days.</time_frame>
    <description>Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Donor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recipients will receive induction chemotherapy (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplantation</intervention_name>
    <description>Recipients will receive donor stem cells 3 days after conditioning therapy is completed.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>hematopoietic stem cell transplant (HSCT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Toposar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Doxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Oncovin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Rasuvo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Apheresis</intervention_name>
    <description>Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.</description>
    <arm_group_label>Donor</arm_group_label>
    <other_name>extracorporeal therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Inclusion Criteria Patient (Recipient):&#xD;
&#xD;
        Patients with hematologic malignancies, myelodysplasia, or myeloproliferative disorders, as&#xD;
        summarized below:&#xD;
&#xD;
        Disease: Chronic Lymphocytic Leukemia; Disease Status: (a) Relapse post-fludarabine, (b)&#xD;
        Non-Complete Remission (CR) after salvage regimen; Age: 18 to 75.&#xD;
&#xD;
        Disease: Hodgkin's and Non-Hodgkin's Lymphoma (all types, including Mantle Cell Lymphoma);&#xD;
        Disease Status: (a) Primary treatment failure, (b) Relapse after autologous stem cell&#xD;
        transplant (SCT), (c) Hepatosplenic gamma/delta T cell lymphoma; Age: 18 to 75.&#xD;
&#xD;
        Disease: Multiple Myeloma; Disease Status: (a) Primary treatment failure, (b) Relapse after&#xD;
        autologous SCT, (c) Non-CR after salvage regimen; Age: 18 to 75.&#xD;
&#xD;
        Disease: Acute Myelogenous Leukemia; Disease Status: (a) In Complete Remission #1, with&#xD;
        high-risk cytogenetics [abnormalities other than t(8;21), t(15;17), or inv(16)], (b) In&#xD;
        Complete Remission #2 or greater; Age: 18 to 75.&#xD;
&#xD;
        Disease: Acute Lymphocytic Leukemia; Disease Status: (a) In Complete Remission #1, with&#xD;
        high-risk cytogenetics [t(9;22) or bcr-abl rearrangement; t(4;11), 1(1;19), t(8;14)], (b)&#xD;
        In Complete Remission #2 or greater; Age: 18 to 75.&#xD;
&#xD;
        Disease: Myelodysplastic Syndrome; Disease Status: (a) refractory anemia with excess blasts&#xD;
        (RAEB), (b) refractory anemia with excess blasts in transformation (RAEB-T) (if blasts are&#xD;
        less than 10% in marrow and blood after induction chemotherapy); Age: 18 to 75.&#xD;
&#xD;
        Disease: Myeloproliferative disorders; Disease Status: (a) Idiopathic myelofibrosis, (b)&#xD;
        Polycythemia vera, (c) Essential thrombocytosis, (d) Chronic myelomonocytic leukemia; Age:&#xD;
        18 to 75.&#xD;
&#xD;
        Disease: Chronic Myelogenous Leukemia (CML); Disease Status: (a) Chronic phase CML, (b)&#xD;
        Accelerated phase CML; Age 50 to 75; (c) Not eligible for myeloablative allogeneic HSCT;&#xD;
        Age: 18 to 50.&#xD;
&#xD;
        Patients 18-75 years of age. Patients older than 75 years of age will be considered on an&#xD;
        individual basis.&#xD;
&#xD;
        Consenting first degree relative matched at 6/6 human leukocyte antigen (HLA) antigens (A,&#xD;
        B, and DR).&#xD;
&#xD;
        Patient or legal guardian must be able to give informed consent.&#xD;
&#xD;
        All previous therapy must be completed at least 2 weeks prior to study entry, and any grade&#xD;
        3 or 4 non-hematologic toxicity of previous therapy must be resolved to grade 2 or less,&#xD;
        unless specified elsewhere.&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) performance status equal to 0 or 1.&#xD;
&#xD;
        Life expectancy of at least 3 months.&#xD;
&#xD;
        Patients with acute leukemia must be in hematologic remission, defined as less than 5%&#xD;
        blasts present in blood or bone marrow.&#xD;
&#xD;
        Left ventricular ejection fraction greater than 45% by either multi-gated acquisition&#xD;
        (MUGA) scan or 2-D echo, obtained within 28 days of enrollment. The cumulative dose of&#xD;
        doxorubicin received by patients will not be considered, as the cardiac ejection fraction&#xD;
        appears to indicate the safe cumulative doxorubicin dose in the setting of etoposide&#xD;
        phosphate, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride&#xD;
        (EPOCH)-based chemotherapy.&#xD;
&#xD;
        Diffusing capacity for carbon monoxide (DLCO) greater than 50% of the expected value when&#xD;
        correlated for hemoglobin (Hb), obtained within 28 days of enrollment.&#xD;
&#xD;
        Creatinine less than or equal to 1.5 mg/dl and creatinine clearance greater than or equal&#xD;
        to 50 ml/min/1.73 m(2).&#xD;
&#xD;
        Serum total bilirubin less than 2.5 mg/dl, and serum alanine aminotransferase (ALT) and&#xD;
        aspartate aminotransferase (AST) values less than or equal to 2.5 times the upper limit of&#xD;
        normal. Values above these levels may be accepted, at the discretion of the principal&#xD;
        investigator (PI) or study chairman, if such elevations are thought to be due to liver&#xD;
        involvement by malignancy. If these values do not normalize during induction chemotherapy,&#xD;
        such patients will not be eligible for the transplant phase of the protocol, and will thus&#xD;
        be taken off study.&#xD;
&#xD;
        Minimum absolute neutrophil count of 1,000 cells/microliter and minimum platelet count&#xD;
        (without transfusion) of 20,000/mm(3).&#xD;
&#xD;
        Inclusion Criteria Donor:&#xD;
&#xD;
        First-degree relative with genotypic identity at 6/6 HLA loci (HLA-A, B and DR).&#xD;
&#xD;
        Ability to give informed consent. For donors under 18 years of age, the donor must complete&#xD;
        an assent form, and the donors legal guardian must complete an informed consent form.&#xD;
&#xD;
        Age 12-75 years. As the potential cerebrovascular and cardiac complications may potentially&#xD;
        increase with age, age 75 has been chosen arbitrarily as the upper age limit. However, if&#xD;
        it is determined after initial accrual of patients in this upper age range that this&#xD;
        procedure is relatively safe, the age range may be extended.&#xD;
&#xD;
        Adequate venous access for peripheral apheresis, or consent to use a temporary central&#xD;
        venous catheter for apheresis.&#xD;
&#xD;
        Donors must be human immunodeficiency virus (HIV) negative, hepatitis B surface antigen&#xD;
        negative, and hepatitis C antibody negative. This is to prevent the possible transmission&#xD;
        of these infections to the recipient.&#xD;
&#xD;
        A donor who is lactating must substitute formula feeding for her infant during the period&#xD;
        of cytokine administration. Filgrastim may be secreted in human milk, although its&#xD;
        bioavailability from this source is not known. Limited clinical data suggest that&#xD;
        short-term administration of filgrastim or sargramostim to neonates is not associated with&#xD;
        adverse outcomes.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Exclusion Criteria Patient:&#xD;
&#xD;
        Active infection that is not responding to antimicrobial therapy.&#xD;
&#xD;
        Active central nervous system (CNS) involvement by malignancy.&#xD;
&#xD;
        HIV infection. There is theoretical concern that the degree of immune suppression&#xD;
        associated with the treatment may result in progression of HIV infection.&#xD;
&#xD;
        Chronic active hepatitis B. Patients may be hepatitis B core antibody positive but must be&#xD;
        surface antigen negative and without evidence of active infection.&#xD;
&#xD;
        Hepatitis C infection.&#xD;
&#xD;
        Pregnant or lactating. Patients of childbearing potential must use an effective method of&#xD;
        contraception. The effects of chemotherapy, the subsequent transplant and the medications&#xD;
        used after the transplant are highly likely to be harmful to a fetus. The effects upon&#xD;
        breast milk are also unknown and may be harmful to the infant.&#xD;
&#xD;
        History of psychiatric disorder which may compromise compliance with transplant protocol,&#xD;
        or which does not allow for appropriate informed consent (as determined by principal&#xD;
        investigator or study chairman).&#xD;
&#xD;
        Exclusion Criteria Donor:&#xD;
&#xD;
        History of psychiatric disorder which may compromise compliance with transplant protocol,&#xD;
        or which does not allow for appropriate informed consent.&#xD;
&#xD;
        History of hypertension that is not controlled by medication, stroke, or severe heart&#xD;
        disease. Individuals with symptomatic angina will be considered to have severe heart&#xD;
        disease will not be eligible to be a donor.&#xD;
&#xD;
        No other medical contraindications to stem cell donation (i.e. severe atherosclerosis,&#xD;
        autoimmune disease, cerebrovascular accident, prior malignancy). Patients with a history of&#xD;
        coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be&#xD;
        considered on a case-by-case basis. Persons with a history of non-hematologic malignancy&#xD;
        must have undergone potentially curative therapy for that malignancy and (1) have had no&#xD;
        evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less&#xD;
        than or equal to 20% at 5 years). Such persons will be considered eligible for stem cell&#xD;
        donation at the discretion of the principal investigator. Prospective donors with a history&#xD;
        of non-hematologic malignancy who have received potentially curative therapy and are in&#xD;
        remission, but whose estimated risk of recurrence is greater than 20% at 5 years, will be&#xD;
        considered on an individual basis in consultation with the National Cancer Institute (NCI)&#xD;
        Institutional Review Board (IRB).&#xD;
&#xD;
        Donors must not be pregnant. The effects of cytokine administration on a fetus are unknown.&#xD;
        Donors of childbearing potential must use an effective method of contraception.&#xD;
&#xD;
        Anemia (Hb less than 11 gm/dl) or thrombocytopenia (platelets less than 100,000 per&#xD;
        microliter).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel H Fowler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Champlin RE. T-cell depletion for bone marrow transplantation: effects on graft rejection, graft-versus-host disease, graft-versus-leukemia, and survival. Cancer Treat Res. 1990;50:99-111. Review.</citation>
    <PMID>1976361</PMID>
  </reference>
  <reference>
    <citation>Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol. 1996 Mar;8(2):96-102. Review.</citation>
    <PMID>8727301</PMID>
  </reference>
  <reference>
    <citation>Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O'Quigley J, Sanders J, Sullivan KM, Witherspoon RP, Deeg HJ, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988 Sep;3(5):445-56.</citation>
    <PMID>3056552</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 8, 2003</study_first_submitted>
  <study_first_submitted_qc>January 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2003</study_first_posted>
  <results_first_submitted>July 28, 2021</results_first_submitted>
  <results_first_submitted_qc>August 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Ronald Gress, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT00051311/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Donor Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 22, 2007</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT00051311/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Recipient Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 14, 2004</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT00051311/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Donor</title>
          <description>Apheresis: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.</description>
        </group>
        <group group_id="P2">
          <title>Recipient</title>
          <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Starting new study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pt. to pursue treatment for progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death of recipient</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recipient taken off study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Donor</title>
          <description>Apheresis: Donors will undergo apheresis to collect stem cells for a stem cell transplant for the recipient.</description>
        </group>
        <group group_id="B2">
          <title>Recipient</title>
          <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.98" spread="12.01"/>
                    <measurement group_id="B2" value="52.27" spread="12.33"/>
                    <measurement group_id="B3" value="52.12" spread="12.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</title>
        <description>Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
        <time_frame>At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</title>
          <description>Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade I GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade II GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade IV GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</title>
        <description>Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
        <time_frame>At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis</title>
          <description>Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash &lt; 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea &gt;1500 ml/d. Grade 4: desquamation and bullae, total bilirubin &gt;15 mg/dl, and pain +/- ileus.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Recipients Who Achieved Donor Chimerism at Day +14</title>
        <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
        <time_frame>Day+14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Recipients Who Achieved Donor Chimerism at Day +14</title>
          <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
          <units>percentage of recipients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100</title>
        <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
        <time_frame>Day+100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100</title>
          <description>Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients</title>
        <description>Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients.</description>
        <time_frame>Up to cycle 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients</title>
          <description>Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients.</description>
          <units>Cycles</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Neutrophil Recovery</title>
        <description>Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days.</description>
        <time_frame>Up to 2 months after stem cell transplant</time_frame>
        <population>The time to neutrophil recovery could not be determined precisely for 1 recipient who received granulocyte transfusions for an active infection following transplantation.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Neutrophil Recovery</title>
          <description>Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days.</description>
          <population>The time to neutrophil recovery could not be determined precisely for 1 recipient who received granulocyte transfusions for an active infection following transplantation.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="7" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Platelet Recovery</title>
        <description>Platelet recovery is defined as &gt;50,000 mm3 platelet cell count after transfusion.</description>
        <time_frame>Up to 2 months after stem cell transplant</time_frame>
        <population>Six recipients were not evaluable for platelet recovery &gt; 20K because their platelet count never fell below that level (n=2) or because they were receiving aggressive platelet transfusions (n=4).</population>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Platelet Recovery</title>
          <description>Platelet recovery is defined as &gt;50,000 mm3 platelet cell count after transfusion.</description>
          <population>Six recipients were not evaluable for platelet recovery &gt; 20K because their platelet count never fell below that level (n=2) or because they were receiving aggressive platelet transfusions (n=4).</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="9" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)</title>
        <description>Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass &gt; 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s).</description>
        <time_frame>At least 100 days after post reduced-intensity stem cell transplantation (RIST).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)</title>
          <description>Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass &gt; 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission or Complete Remission Unconfirmed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Recipients With Non-serious Adverse Events</title>
        <description>Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 58 months and 13 days.</time_frame>
        <population>Adverse events data were only collected for the recipients.</population>
        <group_list>
          <group group_id="O1">
            <title>Recipient</title>
            <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Recipients With Non-serious Adverse Events</title>
          <description>Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence.</description>
          <population>Adverse events data were only collected for the recipients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 58 months and 13 days.</time_frame>
      <desc>Adverse events data were only collected for the recipients.</desc>
      <group_list>
        <group group_id="E1">
          <title>Recipient</title>
          <description>Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.&#xD;
Methotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).&#xD;
Cyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTC 2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DIC (disseminated intravascular coagulation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection)</description>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lymphatics</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transfusion: Platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Transfusion: pRBCs</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pericardial effusion/pericarditis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular tachycardia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Middle ear/hearing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine-Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Keratitis (corneal inflammation/corneal ulceration)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ocular-Other</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ascites (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea (without colostomy)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea for BMT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>GI-Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Melena/GI bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mucositis due to radiation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional symptoms - Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever (in absence of neutropenia, where neutropenia is defined as AGC&lt;1.0x109/L)</sub_title>
                <counts group_id="E1" events="55" subjects_affected="24" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic-Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Allergy-Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Autoimmune reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter-related infection</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="22" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="86" subjects_affected="23" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infection, Other</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myositis (inflammation/damage of muscle)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radiation recall reaction</sub_title>
                <description>(reaction following chemotherapy in the absence of additional radiation therapy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="47" subjects_affected="22" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bilirubin-graft versus host disease (GVHD)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusion capacity (DLCO)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>FEV1</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemoglobin (Hgb)</sub_title>
                <counts group_id="E1" events="54" subjects_affected="28" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="58" subjects_affected="28" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC) for BMT</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="49" subjects_affected="24" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Platelets for BMT</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SGOT (AST)</sub_title>
                <counts group_id="E1" events="36" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>SGPT (ALT)</sub_title>
                <counts group_id="E1" events="37" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight gain-veno-occlusive disease (VOD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Chest pain (non-cardiac and non-pleuritic)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Joint, muscle, or bone (osseous)-Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle weakness (not due to neuropathy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle ache)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy-Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia (incoordination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CNS hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance/learning problems</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neurologic-Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neuropathy motor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Seizure(s)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Renal/GU-Other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Ureteral obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="49" subjects_affected="27" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash-desquamation for BMT</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin-Other</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vascular leak syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ronald Gress</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>240-760-6167</phone>
      <email>Ronald_Gress@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

